Evidence map›Paper›PMID 37000947›Full record

ArticleAnnals of clinical and translational neurology2023

Quantitative determination of SLC2A1 variant functional effects in GLUT1 deficiency syndrome.

Naeimeh Tayebi, Brian Leon-Ricardo, Kevin McCall, Elvisa Mehinovic, Kristin Engelstad, Vincent Huynh, Tychele N Turner, Judy Weisenberg, Liu L Thio, Paul Hruz and 5 more

Open access · goldAbstract read
In one paragraph

Article in Annals of clinical and translational neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Direct targeting of GLUT1 in cancer: A decade of inhibitor discovery and medicinal chemistry insights.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Naeimeh TayebiDepartment of Neurology, Washington University in St Louis, St Louis, Missouri, USA.ORCID 0000-0002-6321-9662
Brian Leon-RicardoDepartment of Neurology, Washington University in St Louis, St Louis, Missouri, USA.
Kevin McCallDepartment of Neurology, Washington University in St Louis, St Louis, Missouri, USA.
Elvisa MehinovicDepartment of Genetics, Washington University in St Louis, St Louis, Missouri, USA.
Kristin EngelstadDepartment of Neurology, Columbia University Irving Medical Center, New York, New York, USA.
Vincent HuynhDepartment of Neurology, Columbia University Irving Medical Center, New York, New York, USA.
Tychele N TurnerDepartment of Genetics, Washington University in St Louis, St Louis, Missouri, USA.
Judy WeisenbergDepartment of Neurology, Washington University in St Louis, St Louis, Missouri, USA.
Liu L ThioDepartment of Neurology, Washington University in St Louis, St Louis, Missouri, USA.
Paul HruzDepartment of Pediatrics, Washington University in St Louis, St Louis, Missouri, USA.
Robin S B WilliamsCentre for Biomedical Sciences, Department of Biological Sciences, Royal Holloway University of London, Egham, UK.ORCID 0000-0002-9826-6020
Darryl C De VivoDepartment of Neurology, Columbia University Irving Medical Center, New York, New York, USA.
Vincent PetitMetafora Biosystems, Paris, France.
Gabe HallerDepartment of Neurology, Washington University in St Louis, St Louis, Missouri, USA.
Christina A GurnettDepartment of Neurology, Washington University in St Louis, St Louis, Missouri, USA.ORCID 0000-0001-9129-315X
Washington University in St. Louis · USColumbia University Irving Medical Center · USLungLife AI (United States) · USRoyal Holloway University of London · GB

Funding

WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
WUIDDRC Supplement-Supporting the health and well-being of children with intellectual and developmental disability during COVID-19 pandemicP50HD103525 · NICHD · WASHINGTON UNIVERSITY · PI JOSEPH D DOUGHERTY, Natasha Marrus · 2020 to 2026
$15.5M
Genetic Risk Factors for Severe ScoliosisR01AR067715 · NIAMS · WASHINGTON UNIVERSITY · PI DOBBS, MATTHEW BARRETT, GURNETT, CHRISTINA · 2015 to 2024
$6.0M
NCATS NIH HHS UL1 TR002345NIAMS NIH HHS R01 AR067715NICHD NIH HHS P50 HD103525NIH HHS P50 HD103525
6 · The paper itself

Abstract

objectiveThe goal of this study is to demonstrate the utility of a growth assay to quantify the functional impact of single nucleotide variants (SNVs) in SLC2A1, the gene responsible for Glut1DS.

methodsThe functional impact of 40 SNVs in SLC2A1 was quantitatively determined in HAP1 cells in which SLC2A1 is required for growth. Donor libraries were introduced into the endogenous SLC2A1 gene in HAP1-Lig4KO cells using CRISPR/Cas9. Cell populations were harvested and sequenced to quantify the effect of variants on growth and generate a functional score. Quantitative functional scores were compared to 3-OMG uptake, SLC2A1 cell surface expression, CADD score, and clinical data, including CSF/blood glucose ratio.

resultsNonsense variants (N = 3) were reduced in cell culture over time resulting in negative scores (mean score: -1.15 ± 0.17), whereas synonymous variants (N = 10) were not depleted (mean score: 0.25 ± 0.12) (P < 2e-16). Missense variants (N = 27) yielded a range of functional scores including slightly negative scores, supporting a partial function and intermediate phenotype. Several variants with normal results on either cell surface expression (p.N34S and p.W65R) or 3-OMG uptake (p.W65R) had negative functional scores. There is a moderate but significant correlation between our functional scores and CADD scores.

interpretationCell growth is useful to quantitatively determine the functional effects of SLC2A1 variants. Nonsense variants were reliably distinguished from benign variants in this in vitro functional assay. For facilitating early diagnosis and therapeutic intervention, future work is needed to determine the functional effect of every possible variant in SLC2A1.

Indexed as

Carbohydrate Metabolism, Inborn ErrorsGlucose Transporter Type 1HumansMonosaccharide Transport ProteinsMutation, MissensePhenotypeGlucose Transporter Type 1Monosaccharide Transport ProteinsSLC2A1 protein, human

Identifiers

PMID37000947
PMCPMC10187726
OpenAlexW4362459664

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.